GLP-1 Agonists in Primary Care: New Cardiovascular Outcomes Data Changes the Prescribing Calculus

The SELECT Extension Data: Why This Matters Now

When the SELECT trial published its primary results in 2023, it made waves for confirming that semaglutide (Ozempic/Wegovy) reduced major adverse cardiovascular events in patients with established cardiovascular disease and obesity — without diabetes as a prerequisite.

New extended follow-up data presented at the American College of Cardiology Annual Scientific Sessions last month deepens this finding with 36-month outcomes that have direct clinical and operational implications for primary care practices managing these patients.

What the Extended Data Shows

The extended follow-up enrolled 17,604 adults (mean BMI 33.4, no diabetes at baseline) with pre-existing cardiovascular disease. At 36 months:

17% relative risk reduction in MACE (major adverse cardiovascular events) vs. placebo
Cardiovascular mortality reduced by 19%
Heart failure hospitalizations reduced by 23%
Kidney disease progression reduced by 22% (a prespecified secondary endpoint gaining increasing clinical attention)

Critically, the cardiovascular benefit appeared independent of weight loss magnitude, suggesting mechanisms beyond body weight reduction — including direct anti-inflammatory effects and potential myocardial metabolic benefits.

The Prescribing Calculus Has Shifted

For primary care physicians managing patients with established cardiovascular disease and obesity (BMI ≥ 27), this data creates a stronger clinical rationale for GLP-1 therapy than weight management alone.

"We're no longer talking about prescribing this for weight loss in cardiovascular patients," said Dr. Carla Simmons, a cardiologist and clinical pharmacologist commenting on the data at ACC. "We're talking about it as a cardiovascular risk reduction strategy that also improves metabolic parameters. That's a different conversation with a different risk-benefit calculus."

The updated 2025 AHA/ACC Heart Failure guidelines — released in November — already reflect this, adding GLP-1 receptor agonists as a Class IIa recommendation for patients with heart failure with preserved ejection fraction and obesity.

Managing the Practice Realities

The clinical case is strengthening. The operational case remains complicated.

Access and Cost: Semaglutide injectable remains among the most expensive medications in primary care, with out-of-pocket costs frequently exceeding $1,000/month without insurance coverage. The manufacturer's patient assistance program covers patients under 400% of the federal poverty level, but the documentation burden falls on practice staff.

Prior Authorization: Commercial payer prior authorization requirements for GLP-1 therapy remain extensive and inconsistent. Practices prescribing at volume have largely moved to dedicated prior authorization staff or third-party prior authorization services.

Supply Chain: Shortage designations were lifted in mid-2025 for most branded products, but compounded semaglutide availability — and the associated patient demand for lower-cost alternatives — continues to create clinical complexity.

Monitoring Protocol: The extended data reinforces the importance of structured monitoring. Recommended protocol:

Baseline: comprehensive metabolic panel, HbA1c, lipids, renal function, thyroid screening
3 months: weight, glucose, BP, tolerance assessment
6 months: comprehensive metabolic panel, renal function
Annually: full metabolic workup, cardiovascular risk reassessment

The Equity Lens

Access to GLP-1 therapy tracks closely with insurance type and socioeconomic status — a disparity that is clinically unjust given the cardiovascular burden in lower-income populations where obesity prevalence is higher. Practices serving Medicaid populations face particularly acute formulary restrictions.

Several states have successfully advocated for GLP-1 coverage on Medicaid formularies for cardiovascular indications. Connecting with your state medical association's advocacy efforts on this specific issue is one of the highest-impact actions a practice can take.

What to Do in Your Practice This Week

Audit your panel: Identify patients with established CVD + BMI ≥ 27 currently not on GLP-1 therapy who might benefit from a cardioprotective indication discussion
Update your prior auth workflow: Ensure your PA team is citing the cardiovascular indication, not just weight management, when applicable
Create a patient resource: Develop a one-page patient-facing summary of the cardiovascular data for shared decision-making conversations
Document the conversation: For patients declining due to cost, document the discussion and the barriers — this creates evidence for population health initiatives and future advocacy